Synbiotics in the Management of Breast Cancer

Thekkekkara, Dithu; Manjula, S. N.; Mishra, Neeraj; Bhatt, Shvetank; Shilpi, Satish

doi:10.1007/978-981-19-7550-9_14

Cited by 2 publications

(4 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…and metabolic patterns (insulin resistance). All these cellular events contribute to inflammation and instigation of EMT to ultimately bring forth carcinogenesis [ 97 ]. Thekkekkara et al [ 97 ], suggest that the pro-biotics and anti-oxidants can be utilised to synergistically treat cancers, and also restore the damaged intestinal barrier, incite immuno-modulation and prevent cancer.…”

Section: Glycation/ages and Gut Microbiome In Cancermentioning

confidence: 99%

“…All these cellular events contribute to inflammation and instigation of EMT to ultimately bring forth carcinogenesis [ 97 ]. Thekkekkara et al [ 97 ], suggest that the pro-biotics and anti-oxidants can be utilised to synergistically treat cancers, and also restore the damaged intestinal barrier, incite immuno-modulation and prevent cancer. Hence, we advocate the synergistic combination of synbiotics (pro-and pre-biotics) and plant-based polyphenols with anti-glycation activity (natural AGE inhibitors) to address the synergistic role of exogenous (dietary) and endogenous AGEs in prompting the inflammatory cascade pertinent to cancers.…”

Section: Glycation/ages and Gut Microbiome In Cancermentioning

confidence: 99%

“…Hence AGEs and LPS stimulate each other in a positive feedback loop to impair gut microbiota and sustain inflammation, by releasing pro-inflammatory cytokines, chemokines, mediators, adhesion molecules and ligands (HMGB1 and S100 proteins) in the micro-milieu. Recent studies have revealed the alteration in composition of gut microbiota and induction of insulin resistance, along with subsequent shift in colonocyte structure, rise in colon permeability, reduction in expression of tight junction proteins, ultimately leading to intestinal epithelial barrier dysfunction, with resultant augmentation of RAGE NF-κB signalling upon exposure to dietary AGEs [94][95][96]. The most interesting fact recently put forth by Reddy et al [91] is that Maillard reactions are detected in the gut bacterial species also besides the host, generating pathogenic protein aggregates in the bacterial species [91].…”

Section: Glycation/ages and Gut Microbiome In Cancermentioning

confidence: 99%

“…AGEs from diet modify the gut microbiota with elicitation of both local and systemic (colonic/gut inflammation) pro-inflammatory signalling and endothelial dysfunction, further leading to pro-tumorigenic inflammation and potential incitation of different cancers, both local and systemic, including buccal, breast, lung, hepato-cellular, gastric, gastro-oesophageal, colon, colorectal, pancreatic, ovarian and cervical cancers [97]. AGEs markedly reshape the gut microbiota profile, inducing gut microbial dysbiosis and exerting detrimental impact on colonic epithelium and enteric neurons, by augmenting protein fermentation/ glycation and attenuating neuronal expression, respectively, paving way for inflammatory conditions like colitis, inflammatory bowel disease and even colo-rectal cancer [96]. Evidence for reversibility of dietary AGEs-induced rise in plasma and tissue AGEs, along with the elimination of colonic inflammation and regaining gut microbial composition, have been provided by van Dongen et al [98] with switch to lowdietary AGEs.…”

Section: Glycation/ages and Gut Microbiome In Cancermentioning

confidence: 99%

See 3 more Smart Citations

AGEs and RAGE: metabolic and molecular signatures of the glycation-inflammation axis in malignant or metastatic cancers

Palanissami,

Paul

2023

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

From attributing mutations to cancers with the advent of cutting-edge genetic technology in recent decades, to re-searching the age-old theory of intrinsic metabolic shift of cancers (Warburg’s glycolysis), the quest for a precise panacea for mainly the metastatic cancers, remains incessant. This review delineates the advanced glycation end product (AGE)-receptor for AGE (RAGE) pathway driven intricate oncogenic cues, budding from the metabolic (glycolytic) reliance of tumour cells, branching into metastatic emergence of malignancies. Strong AGE-RAGE concomitance in metastasis, chemo-resistance and cancer resurgence adversely incite disease progression and patient mortality. At the conjunction of metabolic and metastatic shift of cancers, are the “glycolytically” generated AGEs and AGE-activated RAGE, instigating aberrant molecular pathways, culminating in aggressive malignancies. AGEs as by-products of metabolic insurgence, modify the metabolome, epigenome and microbiome, besides coercing the inter-, intra- and extra-cellular micro-milieu conducive for oncogenic events like epithelial-mesenchymal transition (EMT). AGE-RAGE synergistically elicit ATP surge for surplus energy, autophagy for apoptotic evasion and chemo-resistance, insulin-like growth factor 1 (IGF-1) for meta-inflammation and angiogenesis, high mobility group box-1 (HMGB1) for immune tolerance, S100 proteins for metastasis, and p53 protein attenuation for tumour suppression. AGEs are pronouncedly reported in invasive forms of breast, prostate, colon and pancreatic cancers, higher in patients with cancer than healthy counterparts, and higher in advanced stage than localized phase. Hence, the investigation of person-specific presence of AGEs, soluble RAGE and AGE-activated RAGE can be advocated as impending bio-markers for diagnostic, prognostic and therapeutic purposes, to predict cancer risk in patients with diabetes, obesity, metabolic syndrome as well as general population, to monitor prognosis and metastasis in patients with cancer, and to reckon complications in cancer survivors. Furthermore, clinical reports of exogenous (dietary) and endogenous (internally formed) AGEs in cancer patients, and contemporary clinical trials involving AGE-RAGE axis in cancer are underlined with theranostic implications.

show abstract

Section: Glycation/ages and Gut Microbiome In Cancermentioning

confidence: 99%

Section: Glycation/ages and Gut Microbiome In Cancermentioning

confidence: 99%